Overview

Study to Assess the Safety and Efficacy of ONZETRA® Xsail® for the Acute Treatment of Episodic Migraine With or Without Aura in Adolescents

Status:
Recruiting

Trial end date:
2023-08-31

Target enrollment:

Participant gender:

Summary

This study will be conducted to evaluate the safety and efficacy of sumatriptan nasal powder (AVP-825) compared to placebo in the acute treatment of migraine in adolescent participants, 12 through 17 years of age.

Phase:

Phase 3

Details

Lead Sponsor:

Avanir Pharmaceuticals
Currax Pharmaceuticals

Treatments:

Sumatriptan